Payment overview · 2025
General Payments
$411.61
22 reported records · 12 companies
Healthcare provider profile · identity verified
Gary Douglas Thomas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WINFIELD, AL · NPI 1407895261
Verified facts
What the public records show
CMS Open Payments records show Gary Douglas Thomas, M.D. received $411.61 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.88 | 24.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.29 | 12.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.62 | 10.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.82 | 9.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.25 | 8.3% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.98 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.27 | 5.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.21 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.24 | 4.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.21 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.66 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.18 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.61 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.88 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $69.50 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
332 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 151 |
| Gabapentin | Gabapentin | 497 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 95 |
| Lisinopril | Lisinopril | 446 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 436 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 104 |
| Losartan Potassium | Losartan Potassium | 403 | 94 |
| Furosemide | Furosemide | 335 | 76 |
| Eliquis | Apixaban | 332 | 48 |
| Metformin Hcl | Metformin Hcl | 311 | 72 |
| Tramadol Hcl | Tramadol Hcl | 298 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 62 |
| Trazodone Hcl | Trazodone Hcl | 291 | 57 |
| Omeprazole | Omeprazole | 269 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 66 |
| Potassium Chloride | Potassium Chloride | 229 | 51 |
| Celecoxib | Celecoxib | 225 | 55 |
| Spironolactone | Spironolactone | 221 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 46 |
| Meloxicam | Meloxicam | 159 | 35 |
| Buspirone Hcl | Buspirone Hcl | 152 | 22 |
| Glimepiride | Glimepiride | 147 | 34 |
| Ozempic | Semaglutide | 147 | 23 |
| Alprazolam | Alprazolam | 146 | 22 |
| Ezetimibe | Ezetimibe | 137 | 34 |
| Famotidine | Famotidine | 136 | 29 |
| Sertraline Hcl | Sertraline Hcl | 130 | 24 |
| Carvedilol | Carvedilol | 129 | 23 |
| Clonazepam | Clonazepam | 125 | 22 |
| Methocarbamol | Methocarbamol | 124 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 29 |
| Farxiga | Dapagliflozin Propanediol | 116 | 17 |
| Alendronate Sodium | Alendronate Sodium | 111 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 23 |
| Mounjaro | Tirzepatide | 98 | 17 |
| Pregabalin | Pregabalin | 95 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 27 |
| Mirtazapine | Mirtazapine | 89 | 17 |
| Ramipril | Ramipril | 89 | 17 |
| Allopurinol | Allopurinol | 87 | 15 |
| Prednisone | Prednisone | 87 | 56 |
| Labetalol Hcl | Labetalol Hcl | 81 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 16 |
| Atenolol | Atenolol | 79 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 15 |
| Memantine Hcl | Memantine Hcl | 76 | 11 |
| Simvastatin | Simvastatin | 76 | 20 |
| Montelukast Sodium | Montelukast Sodium | 73 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 12 |
| Donepezil Hcl | Donepezil Hcl | 70 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 16 |
| Jardiance | Empagliflozin | 68 | suppressed |
| Lorazepam | Lorazepam | 67 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Finasteride | Finasteride | 52 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 16 |
| Fenofibrate | Fenofibrate | 50 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Nystatin | Nystatin | 47 | 16 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 28 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Estradiol | Estradiol | 41 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 36 |
| Invokana | Canagliflozin | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 15 |
| Glipizide | Glipizide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.61 · 22 records | Amgen Inc. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, INGREZZA, MOUNJARO, Ozempic, PREVNAR 20, REPATHA, REXULTI, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error